All In Biotech

Drug Trial Radar · NCT06731868

Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia

A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetic Characteristics of Multiple Doses of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia

Last checked: Nov 19, 2026Latest source record: Jan 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jan 14, 2025

Primary completion

Oct 31, 2025

Study completion Oct 31, 2025

Sponsor

Lead sponsor
Luye Pharma Group Ltd.Industry
Sponsor type
Industry
First posted
Dec 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled parallel-group trial to evaluate the safety, tolerability, preliminary efficacy and PK characteristics of multiple doses of LPM3770164 sustained-release tablets in TD patients.

Conditions

  • Tardive Dyskinesia (TD)

Interventions

  • LPM3770164 sustained release tablet 5 mgDrug

    LPM3770164 sustained release tablet once daily oral dosage at 5 mg for 6 weeks

  • LPM3770164 sustained release tablet 10 mgDrug

    LPM3770164 sustained release tablet once daily oral dosage at 10 mg for 6 weeks.

  • LPM3770164 sustained release tablet 20 mgDrug

    LPM3770164 sustained release tablet once daily oral dosage at 20 mg for 6 weeks.

  • LPM3770164 sustained release tablet simulantDrug

    LPM3770164 sustained release tablet simulant once daily oral for 6 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse eventTime frame: From baseline to Week 8
  2. Change in Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total ScoreTime frame: From baseline to Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Mental Health Center

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.